6.1321
前日終値:
$5.73
開ける:
$5.87
24時間の取引高:
1.54M
Relative Volume:
0.66
時価総額:
$1.88B
収益:
$9.47B
当期純損益:
$-178.00M
株価収益率:
-12.78
EPS:
-0.48
ネットキャッシュフロー:
$1.01B
1週間 パフォーマンス:
+14.82%
1か月 パフォーマンス:
+31.05%
6か月 パフォーマンス:
-16.62%
1年 パフォーマンス:
-5.41%
Bausch Health Companies Inc Stock (BHC) Company Profile
名前
Bausch Health Companies Inc
セクター
電話
514-744-6792
住所
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
BHC を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
BHC
Bausch Health Companies Inc
|
6.14 | 1.88B | 9.47B | -178.00M | 1.01B | -0.48 |
![]()
RGC
Regencell Bioscience Holdings Ltd
|
63.68 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
![]()
ZTS
Zoetis Inc
|
156.35 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
HLN
Haleon Plc Adr
|
10.47 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 47.60B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.07 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-08-02 | ダウングレード | Piper Sandler | Neutral → Underweight |
2024-07-10 | 開始されました | Raymond James | Mkt Perform |
2023-09-20 | アップグレード | Jefferies | Hold → Buy |
2023-06-16 | ダウングレード | TD Cowen | Outperform → Market Perform |
2022-07-29 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2022-07-29 | ダウングレード | Truist | Buy → Hold |
2022-07-28 | ダウングレード | JP Morgan | Overweight → Neutral |
2022-06-13 | 再開されました | JP Morgan | Overweight |
2021-03-24 | ダウングレード | BofA Securities | Neutral → Underperform |
2021-02-17 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2021-01-22 | ダウングレード | Piper Sandler | Overweight → Neutral |
2020-09-17 | アップグレード | BofA Securities | Underperform → Neutral |
2020-08-24 | 繰り返されました | H.C. Wainwright | Buy |
2020-06-17 | 繰り返されました | H.C. Wainwright | Buy |
2020-04-24 | 開始されました | Citigroup | Buy |
2020-04-02 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-01-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2020-01-22 | アップグレード | Wells Fargo | Underweight → Equal Weight |
2019-12-12 | アップグレード | JP Morgan | Neutral → Overweight |
2019-12-02 | 開始されました | Goldman | Neutral |
2019-10-25 | 開始されました | Cowen | Outperform |
2019-09-12 | 開始されました | Guggenheim | Buy |
2019-08-15 | アップグレード | TD Securities | Hold → Buy |
2019-07-19 | 開始されました | Wolfe Research | Outperform |
2019-06-11 | 再開されました | Barclays | Overweight |
2019-05-13 | アップグレード | JP Morgan | Underweight → Neutral |
2019-03-20 | 開始されました | SunTrust | Buy |
2019-01-02 | アップグレード | Piper Jaffray | Neutral → Overweight |
2018-11-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2018-09-13 | アップグレード | Piper Jaffray | Underweight → Neutral |
すべてを表示
Bausch Health Companies Inc (BHC) 最新ニュース
John Paulson buying at Bausch Health Companies (BHC) - The Globe and Mail
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference - The Globe and Mail
Director buying at Bausch Health Companies (BHC) - The Globe and Mail
Bausch Health: Repricing Potential Driven By Deleveraging (NYSE:BHC) - Seeking Alpha
Bausch Health ticks higher following large director stock purchase - MSN
Bausch Health Companies Inc. (TSE:BHC) Director John Paulson Acquires 754,134 Shares - MarketBeat
Bausch Health (BHC) Jumps 8.5% as Exec Hikes Stake; Subsidiaries Raise Over $3-Billion Fresh Funds - Yahoo Finance
LOOK: These 10 Stocks Just Stole The Show - Insider Monkey
Bausch Health (BHC) Rises After Director's $15M Share Purchase - GuruFocus
Bausch Health Companies Stock Price, Quotes and Forecasts | NYSE:BHC - Benzinga
Hedge Fund and Insider Trading News: Philippe Laffont, Warren Buffett, Bill Ackman, Farallon Capital, Bausch Health Companies Inc (BHC), MicroStrategy Inc (MSTR), and More - Insider Monkey
Rising Demand in Traveler's Diarrhea MarketTop Developments, - openPR.com
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets - The Globe and Mail
Benzodiazepine Drugs Market Trends, Growth Forecast, and Top - openPR.com
SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Bausch + Lomb Launching Senior Secured Notes Offering and Refinancing Credit Agreement - marketscreener.com
Bausch + Lomb Brief: Launching Senior Secured Notes Offering and Refinancing Credit Agreement - marketscreener.com
Huntington's Disease Market Grows with Increased Genetic - openPR.com
Reconstructive Surgery Market Trends, Size & Growth Forecast - openPR.com
The most oversold and overbought stocks on the TSX - The Globe and Mail
Two Sigma Investments LP Boosts Holdings in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Why Is Bausch (BHC) Down 13% Since Last Earnings Report? - Yahoo Finance
Intraocular Lens Market Is Booming So Rapidly 2025-2032 -Bausch - openPR.com
With 51% institutional ownership, Bausch Health Companies Inc. (NYSE:BHC) is a favorite amongst the big guns - Yahoo Finance
Choroidal Neovascularization Market: Insights Into Retinal - openPR.com
Verteporfin Market Projected to Witness Increased UtilizationNovartis, Valeant Pharmaceuticals - openPR.com
Actinic Keratosis Market Poised Boom | Almirall, S.A, Bausch - openPR.com
Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To Know - Yahoo Finance
Bausch Health’s $7.9 Billion Refinancing Transaction - Global Legal Chronicle
Zacks Research Has Bearish Forecast for BHC Q2 Earnings - Defense World
Research Analysts Offer Predictions for TSE:BHC Q2 Earnings - Defense World
Equities Analysts Set Expectations for BHC Q3 Earnings - Defense World
Colonoscopy Bowel Preparation Drugs Market Detailed Analysis - openPR.com
Facial Injectable Market Forecasts Report 2025-2030, - GlobeNewswire
Bausch Health Companies IncEnters Agreements With Icahn, Paulson, Kavanagh GroupsSEC Filing - marketscreener.com
Bausch Health and Bausch + Lomb Brief: Cos Have Cited Amendment to Definitive Proxy Statement Relating to 2025 Annual Meeting of Shareholders On May 21, 2025 - marketscreener.com
Bausch + Lomb’s New Board Agreements Announced - TipRanks
Bausch Health Signs New Board Agreements - TipRanks
Bausch Health Companies Inc. (NYSE:BHC) Receives Average Rating of “Reduce” from Analysts - Defense World
Bausch Health Companies (TSE:BHC) Stock Price Up 1.4% – Time to Buy? - Defense World
Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com | FinancialContent - FinancialContent
Balyasny Asset Management L.P. Invests $97,000 in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Global Cataract Surgery Devices Market to grow at a CAGR of 5.50% - openPR.com
Bausch Health Companies Inc. (NYSE:BHC) Stake Lessened by Stifel Financial Corp - Defense World
Bausch, Mylan Settle Patent Suit Over Generic IBS Drugs - Law360
Bausch Health’s CFO Steps In as Interim CAO - TipRanks
India Ophthalmic Devices Market Forecast Report 2025-2033, - GlobeNewswire
Genital Herpes Treatment Market reached US$ 1,143.19 million - openPR.com
Hyperopia Treatment Market Growth, Trends & Opportunities - openPR.com
Bausch Health Elects New Board at Annual Meeting - TipRanks
Bausch Health Companies Inc (BHC) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):